SCHEMBL25308429

SCHEMBL25308429

COc1c(C2CNC2)ccnc1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCNT1 O60563 6/20 0.38
▸ CDK9 P50750 6/20 0.38
▸ HTR2A P28223 1/20 0.37
▸ HTR2C P28335 1/20 0.37
▸ ALOX5AP P20292 5/20 0.35
▸ FEN1 P39748 5/20 0.35
▸ CHRNB4 P30926 4/20 0.34
▸ CHRNA3 P32297 4/20 0.34
▸ CHRNB2 P17787 3/20 0.34
▸ CHRNA4 P43681 3/20 0.34
▸ CHRNA1 P02708 1/20 0.34
▸ ESR1 P03372 1/20 0.34
▸ CHRNG P07510 1/20 0.34
▸ CHRNB1 P11230 1/20 0.34
▸ CHRNA5 P30532 1/20 0.34
▸ CHRNA7 P36544 1/20 0.34
▸ HTR3A P46098 1/20 0.34
▸ CHRND Q07001 1/20 0.34
▸ CHRNA2 Q15822 1/20 0.34
▸ HTR1A P08908 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25306711 0.77 ALOX5AP (0.37) CCNT1CDK9HTR2AHTR2CALOX5AP
SCHEMBL15529670 0.70 CHRNB4 (0.45) CHRNB4CHRNA3CHRNB2CHRNA4CHRNA1
SCHEMBL25308445 0.69 ALOX5AP (0.44) CCNT1CDK9ALOX5APFEN1
SCHEMBL25308469 0.69 HTR2A (0.38) HTR2AHTR2CALOX5APFEN1CHRNB4
SCHEMBL31250394 0.69 HTR2A (0.38) HTR2AHTR2CALOX5APFEN1CHRNB4
SCHEMBL28799700 0.68 ALOX5AP (0.38) ALOX5APFEN1HTR1ASLC6A2SLC6A4
SCHEMBL25306278 0.68 CCNT1 (0.38) CCNT1CDK9CHRNB4CHRNA3CHRNB2
SCHEMBL31250386 0.68 CCNT1 (0.38) CCNT1CDK9CHRNB4CHRNA3CHRNB2
SCHEMBL4375741 0.67 GAK (0.38) —
SCHEMBL15112982 0.66 MAOA (0.35) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250215029-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. 2025-07-03 — — US disclosed
EP-4463459-A1 STAT MODULATORS AND USES THEREOF Recludix Pharma, Inc. (US) 2024-11-20 — — EP disclosed
CN-118804917-A STAT modulators and uses thereof 瑞克鲁迪克斯制药股份有限公司 2024-10-18 — — CN disclosed
WO-2023133336-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. (US) 2023-07-13 — — WO disclosed
WO-2023133336-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. (US) 2023-07-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250215029-A1 STAT MODULATORS AND USES THEREOF STAT6, STAT3, STAT5A CCNT1 2276/4885CDK9 614/4885HTR2A 3914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback